Please select the option that best describes you:
What clinical factors impact your upfront treatment decisions in transplant-ineligible MM?
How do you factor in patient age, frailty, patients with underlying organ dysfunction, or other clinical features?
Do you still consider CyBorD or RVD lite since the advent of the MAIA results?
Answer from: Medical Oncologist at Academic Institution
My approach is to start with up-front adjustments in choice of drugs, dose, and schedule based upon many factors: age, organ function/other comorbidities, concurrent medications, insurance/other economic factors, personal physical mobility, and access to transportation, patient goals, etc.Myeloma tr...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In general, one has to consider patient-related and disease-related factors while picking a therapeutic approach. Simplistically, we would consider RVd-lite for patients who have high-risk features in the TI setting and DRd for standard risk patients (or high risk patients with pre-existing neuropat...
Answer from: Medical Oncologist at Academic Institution
The treatment selection depends on a combination of factors including the risk status based on the revised international staging system, presence of renal insufficiency, functional status of the patients, comorbidities as well as patient preferences. Other presenting features, particularly symptoms ...